Corporate
2017.03.01
Lumosa scientist spoke at 2017 International Stroke Conference
Lumosa Therapeutics Co., Ltd. (Lumosa, 6535.TWO) announced the preclinical study results of its drug candidate for the treatment of acute ischemic stroke at the International Stroke Conference 2017 (ISC).
ISC, a premier scientific conference organized by the American Heart Association (AHA), is the world’s largest meeting, where stroke related basic, clinical and translational sciences are presented and discussed.
The 2017 ISC was held in Houston, USA, on February 22~24. Lumosa’s Dr. Mimi Yeh gave a presentation titled “A Novel Multi-function Small Molecule for the Treatment of Acute Ischemic Stroke in Rodent and Non-human Primate,” in Experimental mechanisms and Models oral session on February 23 CST. Her presentation received positive feedbacks and drew enthusiastic interest from the audience as international medical and research communities have been eagerly await for a novel, safe, and effective acute ischemic stroke treatment. This is the third presence by Lumosa on the podium of ISC. Lumosa’s study was chosen as one of top 10% AHA abstract in its first attendance at the ISC in 2014.
Acute ischemic stroke accounts for 80% of the cerebral strokes, yet there has not been a new drug addressing this unmet medical needs since the launch of rtPA more than 20 years ago. Due to the risk of cerebral hemorrhage and other restrictive conditions, only a very small group of stroke patients are eligible for rtPA treatment. Many stroke clinicians expressed their high hope for Lumosa’s safer and dual-action (thrombolytic and neuro-protective) drug candidate to enter the clinical phase.
Dr. Wendy Huang, CEO of Lumosa, stated that the company plans to submit an Investigational New Drug (IND) application to the US FDA in the first half of 2017. Lumosa has held several advisory meetings with subject matter experts and key opinion leaders globally to ensure the international clinical development program is executed successfully and expediently. Lumosa is very encouraged by the experts' positive feedbacks and their interest in participating in Lumosa’s upcoming clinical studies, which strengthened the company’s confidence in the outlook of our product under development.
ISC, a premier scientific conference organized by the American Heart Association (AHA), is the world’s largest meeting, where stroke related basic, clinical and translational sciences are presented and discussed.
The 2017 ISC was held in Houston, USA, on February 22~24. Lumosa’s Dr. Mimi Yeh gave a presentation titled “A Novel Multi-function Small Molecule for the Treatment of Acute Ischemic Stroke in Rodent and Non-human Primate,” in Experimental mechanisms and Models oral session on February 23 CST. Her presentation received positive feedbacks and drew enthusiastic interest from the audience as international medical and research communities have been eagerly await for a novel, safe, and effective acute ischemic stroke treatment. This is the third presence by Lumosa on the podium of ISC. Lumosa’s study was chosen as one of top 10% AHA abstract in its first attendance at the ISC in 2014.
Acute ischemic stroke accounts for 80% of the cerebral strokes, yet there has not been a new drug addressing this unmet medical needs since the launch of rtPA more than 20 years ago. Due to the risk of cerebral hemorrhage and other restrictive conditions, only a very small group of stroke patients are eligible for rtPA treatment. Many stroke clinicians expressed their high hope for Lumosa’s safer and dual-action (thrombolytic and neuro-protective) drug candidate to enter the clinical phase.
Dr. Wendy Huang, CEO of Lumosa, stated that the company plans to submit an Investigational New Drug (IND) application to the US FDA in the first half of 2017. Lumosa has held several advisory meetings with subject matter experts and key opinion leaders globally to ensure the international clinical development program is executed successfully and expediently. Lumosa is very encouraged by the experts' positive feedbacks and their interest in participating in Lumosa’s upcoming clinical studies, which strengthened the company’s confidence in the outlook of our product under development.
